Abstract: Prognostic Factors for the Survival of 467 Patients with Small Cell Lung CancerChaoWU, Shunchang JIAOCorrespondence to: Shunchang JIAO, E-mail: jiaosc@ vip.sina.comDepartment of Medical Oncology, PLA General Hospital, Beijing 100853, ChinaAbstract Objective: To analyze the prognostic factors of patients with small cell lung cancer ( SCLC ). Methods: Clinical datawere collected from 467 patients with small cell lung cancer ( SCLC ) who were diagnosed through histopathology or cytology. We ana-lyzed whether some factors influenced survival time. Kaplan-Meier, COX multivariate proportional hazards model, and Log-rank testwere used to analyze the prognostic factors. Results: The 12-month, 24-month, and 36-month survival rates were 75.94%, 44.76%, and32.05%, respectively. The rates were 81.72%; 54.95%; and 41.09% in limited disease ( LD ) patients and 66.81%; 25.77%; and 17.06%in extensive disease ( ED ) patients. The median survival time ( MST ) of all the patients was 22 months, 27 months in LD, and 17months in ED. Univariate analyses indicated that age, stage, liver metastasis, operation, chemotherapy, radiotherapy, efficacy offirst-line chemotherapy, the cycle number of first-line chemotherapy, and the levels of hemoglobin (Hb), lactate dehydrogenase (LDH ), CYFRA 21-1, and neuron-specific enolase ( NSE ) significantly influenced survival of SCLC. The multivariate analyses suggestthat radiotherapy, the total number of cycles of chemotherapy, the efficacy of first-line chemotherapy, and CYFRA 21-1 level are inde-pendent prognostic factors of survival. Conclusion: The use of radiotherapy, the total number of cycles of chemotherapy, the efficacy offirst-line chemotherapy, and the level of the CYFRA 21-1 are important prognostic factors for patients with SCLC.Keywords Small cell lung cancer; Chemotherapy; Radiotherapy; Operation; Prognosis